-
摘要:
全程新辅助治疗(total neoadjuvant therapy, TNT)即将直肠癌术后辅助化疗提至术前。术前进行新辅助化疗和同步放化疗,旨在提高患者化疗依从性及远期生存。国内有关该治疗模式的报道较少,本文就该模式治疗直肠癌的相关研究作一综述,以提高对直肠癌围手术期辅助治疗的认识,促进对直肠癌综合治疗模式的探索。
Abstract:Total neoadjuvant therapy (TNT) transfers postoperative adjuvant chemotherapy for rectal cancer to preoperative surgery. Preoperative neoadjuvant chemotherapy followed by concurrent chemoradiotherapy is designed to improve patient compliance and long-term survival. There are few reports on this mode of treatment in China. This article reviews the relevant researches about this mode for rectal cancer, to improve the understanding of perioperative adjuvant treatment for rectal cancer and promote the exploration of the comprehensive treatment mode for rectal cancer.
-
Key words:
- Rectal cancer /
- Induction chemotherapy /
- Total neoadjuvant therapy /
- Clinical trials
-
-
表 1 TNT相关临床研究
Table 1 Clinical studies of TNT
-
[1] International Agency for Research on Cancer. World cancer report 2014[M]. Stewart BW, Wild CP ed: Lyon, 2014.
[2] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. Ca Cancer J Clin, 2016, 66(2): 115-32. doi: 10.3322/caac.21338
[3] Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017[J]. CA Cancer J Clin, 2017, 67(3): 177-93. doi: 10.3322/caac.v67.3
[4] Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017[J]. CA Cancer J Clin, 2017, 67(1): 7-30. doi: 10.3322/caac.21387
[5] Havenga K, Enker WE, Norstein J, et al. Improved survival and local control after total mesorectal excision or D3 lymphadenectomy in the treatment of primary rectal cancer: an international analysis of 1411 patients[J]. Eur J Surg Oncol, 1999, 25(4): 368-74. doi: 10.1053/ejso.1999.0659
[6] Nesbakken A, Nygaard K, Westerheim O, et al. Local recurrence after mesorectal excision for rectal cancer[J]. Eur J Surg Oncol, 2002, 28(2): 126-34. doi: 10.1053/ejso.2001.1231
[7] Bosset JF, Collette L, Calais G, et al. Chemotherapy with Preoperative Radiotherapy in Rectal Cancer[J]. New Engl J Med, 2006, 355(11): 1114-23. doi: 10.1056/NEJMoa060829
[8] Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial[J]. Lancet, 2009, 373(9666): 811-20. doi: 10.1016/S0140-6736(09)60484-0
[9] Methy N, Bedenne L, Conroy T, et al. Surrogate end points for overall survival and local control in neoadjuvant rectal cancer trials: statistical evaluation based on the FFCD 9203 trial[J]. Ann Oncol, 2010, 21(3): 518-24. doi: 10.1093/annonc/mdp340
[10] Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer[J]. N Engl J Med, 2004, 351(17): 1731-40. doi: 10.1056/NEJMoa040694
[11] Gérard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203[J]. J Clin Oncol, 2006, 24(28): 4620-5. doi: 10.1200/JCO.2006.06.7629
[12] Collette L, Bosset JF, Den DM, et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group[J]. J Clin Oncol, 2007, 25(28): 4379-86. doi: 10.1200/JCO.2007.11.9685
[13] Bosset JF, Calais G, Mineur L, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study[J]. Lancet Oncology, 2014, 15(2): 184-90. doi: 10.1016/S1470-2045(13)70599-0
[14] Cercek A, Roxburgh CS, Strombom P, et al. Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer[J]. JAMA Oncol, 2018, 4(6): e180071. doi: 10.1001/jamaoncol.2018.0071
[15] Chau I, Brown G, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer[J]. J Clin Oncol, 2006, 24(4): 668-74. doi: 10.1200/JCO.2005.04.4875
[16] Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer[J]. J Clin Oncol, 2004, 22(11): 2084-91. doi: 10.1200/JCO.2004.11.069
[17] Frickhofen N, Beck FJ, Jung B, et al. Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil[J]. Ann Oncol, 2002, 13(5): 797-801. doi: 10.1093/annonc/mdf035
[18] Saif MW, Garcon MC, Rodriguez G, et al. Bolus 5-fluorouracil as an alternative in patients with cardiotoxicity associated with infusion 5-fluorouracil and capecitabine: a case series[J]. In Vivo, 2013, 27(4): 531-4. http://europepmc.org/abstract/med/23812226
[19] Saif MW, Smith M, Maloney A. The First Case of Severe Takotsubo Cardiomyopathy Associated with 5-Fluorouracil in a Patient with Abnormalities of Both Dihydropyrimidine Dehydrogenase (DPYD) and Thymidylate Synthase (TYMS) Genes[J]. Cureus, 2016, 8(9): e783.
[20] Chua YJ, Barbachano Y, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial[J]. Lancet Oncol, 2010, 11(3): 241-8. doi: 10.1016/S1470-2045(09)70381-X
[21] Schou JV, Larsen FO, Rasch L, et al. Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before total mesorectal excision in patients with locally advanced rectal cancer[J]. Ann Oncol, 2012, 23(10): 2627-33. doi: 10.1093/annonc/mds056
[22] Nogué M, Salud A, Vicente P, et al. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study[J]. Oncologist, 2011, 16(5): 614-20. doi: 10.1634/theoncologist.2010-0285
[23] Fernández-Martos C, Pericay C, Aparicio J, et al. Phase Ⅱ, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study[J]. J Clin Oncol, 2010, 28(5): 859-65. doi: 10.1200/JCO.2009.25.8541
[24] Fernández-Martos C, Garcia-Albeniz X, Pericay C, et al. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term, results of the Spanish GCR-3 phase Ⅱ randomized trial[J]. Ann Oncol, 2015, 26(8): 1722-8. doi: 10.1093/annonc/mdv223
[25] Dewdney A, Cunningham D, Tabernero J, et al. Multicenter Randomized Phase Ⅱ Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuximab Followed by Total Mesorectal Excision in Patients With High-Risk Rectal Cancer (EXPERT-C)[J]. J Clin Oncol, 2012, 30(14): 1620-7. doi: 10.1200/JCO.2011.39.6036
[26] Patel UB, Taylor F, Blomqvist L, et al. Magnetic Resonance Imaging-Detected Tumor Response for Locally Advanced Rectal Cancer Predicts Survival Outcomes: MERCURY Experience[J]. J Clin Oncol, 2011, 29(28): 3753-60. doi: 10.1200/JCO.2011.34.9068
[27] Sclafani F, Brown G, Cunningham D, et al. PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer[J]. Ann Oncol, 2016, 27(8): 1557-65. doi: 10.1093/annonc/mdw215
[28] Maréchal R, Vos B, Polus M, et al. Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase Ⅱ study[J]. Ann Oncol, 2012, 23(6): 1525-30. doi: 10.1093/annonc/mdr473
[29] Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy[J]. Int J Colorectal Dis, 1998, 13(1): 54-5. doi: 10.1007/s003840050134
[30] Fokas E, Liersch T, Fietkau R, et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial[J]. J Clin Oncol, 2014, 32(15): 1554-62. doi: 10.1200/JCO.2013.54.3769
[31] Pham TT, Liney G, Wong K, et al. Study protocol: multi-parametric magnetic resonance imaging for therapeutic response prediction in rectal cancer[J]. BMC Cancer, 2017, 17(1): 465. doi: 10.1186/s12885-017-3449-4
[32] Neri E, Guidi E, Pancrazi F, et al. MRI tumor volume reduction rate vs tumor regression grade in the pre-operative re-staging of locally advanced rectal cancer after chemo-radiotherapy[J]. Eur J Radiol, 2015, 84(12): 2438-43. doi: 10.1016/j.ejrad.2015.08.008
[33] Siddiqui MR, Bhoday J, Battersby NJ, et al. Defining response to radiotherapy in rectal cancer using magnetic resonance imaging and histopathological scales[J]. World J Gastroenterol, 2016, 22(37): 8414-34. doi: 10.3748/wjg.v22.i37.8414
[34] van der Paardt Mp, Zagers MB, Beets-Tan RG, et al. Patients who undergo preoperative chemoradiotherapy for locally advanced rectal cancer restaged by using diagnostic MR imaging: a systematic review and meta-analysis[J]. Radiology, 2013, 269(1): 101-12. doi: 10.1148/radiol.13122833
[35] Sclafani F, Brown G, Cunningham D, et al. Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer[J]. Br J Cancer, 2017, 117(10): 1478-85. doi: 10.1038/bjc.2017.320
[36] Hofheinz RD, Wenz F, Post S, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial[J]. Lancet Oncol, 2012, 13(6): 579-88. doi: 10.1016/S1470-2045(12)70116-X
[37] Ramani VS, Sun MA, Montazeri A, et al. Preoperative chemoradiotherapy for rectal cancer: a comparison between intravenous 5-fluorouracil and oral capecitabine[J]. Colorectal Dis, 2010, 12 Suppl 2: 37-46.
[38] Allegra CJ, Yothers G, O'Connell MJ, et al. Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase Ⅲ Randomized Clinical Trial[J]. J Natl Cancer Inst, 2015, 107(11). http://www.ncbi.nlm.nih.gov/pubmed/26374429
[39] Aschele C, Cionini L, Lonardi S, et al. Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase Ⅲ Trial[J]. J Clin Oncol, 2011, 29(20): 2773-80. doi: 10.1200/JCO.2010.34.4911
[40] Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data.[J]. Lancet Oncology, 2010, 11(9): 835-44. doi: 10.1016/S1470-2045(10)70172-8
[41] Habrgama A, Perez RO, Wynn G, et al. Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization[J]. Dis Colon Rectum, 2010, 53(12): 1692-8. doi: 10.1007/DCR.0b013e3181f42b89
[42] Pastor C, Subtil JC, Sola J, et al. Accuracy of endoscopic ultrasound to assess tumor response after neoadjuvant treatment in rectal cancer: can we trust the findings?[J]. Dis Colon Rectum, 2011, 54(9): 1141-6. doi: 10.1097/DCR.0b013e31821c4a60
[43] Sassen S, de Booij M, Sosef M, et al. Locally advanced rectal cancer: is diffusion weighted MRI helpful for the identification of complete responders (ypT0N0) after neoadjuvant chemoradiation therapy?[J]. Eur Radiol, 2013, 23(12): 3440-9. doi: 10.1007/s00330-013-2956-1
[44] Renehan AG, Malcomson L, Emsley R, et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis[J]. Lancet Oncol, 2015, 17(2): 174-83. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00467-2/abstract?code=lancet-site
[45] Hupkens BJP, Martens MH, Stoot JH, et al. Quality of Life in Rectal Cancer Patients After Chemoradiation: Watch-and-Wait Policy Versus Standard Resection-A Matched-Controlled Study[J]. Dis Colon Rectum, 2017, 60(10): 1032-40. doi: 10.1097/DCR.0000000000000862
[46] Brännström F, Bjerregaard JK, Winbladh A, et al. Multidisciplinary team conferences promote treatment according to guidelines in rectal cancer[J]. Acta Oncol, 2015, 54(4): 447-53. doi: 10.3109/0284186X.2014.952387
[47] Richardson B, Preskitt J, Lichliter W, et al. The effect of multidisciplinary teams for rectal cancer on delivery of care and patient outcome: has the use of multidisciplinary teams for rectal cancer affected the utilization of available resources, proportion of patients meeting the standard of care, and does this translate into changes in patient outcome?[J]. Am J Surg, 2016, 211(1): 46-52. doi: 10.1016/j.amjsurg.2015.08.015
[48] Lan YT, Jiang JK, Chang SC, et al. Improved outcomes of colorectal cancer patients with liver metastases in the era of the multidisciplinary teams[J]. Int J Colorectal Dis, 2016, 31(2): 403-11. doi: 10.1007/s00384-015-2459-4
[49] Wille-Jørgensen P, Sparre P, Glenthøj A, et al. Result of the implementation of multidisciplinary teams in rectal cancer[J]. Colorectal Dis, 2013, 15(4): 410-3. doi: 10.1111/codi.2013.15.issue-4
[50] Kozak VN, Khorana AA, Amarnath S, et al. Multidisciplinary Clinics for Colorectal Cancer Care Reduces Treatment Time[J]. Clin Colorectal Cancer, 2017, 16(4): 366-71. doi: 10.1016/j.clcc.2017.03.020
[51] Nikolovski Z, Watters DAK, Stupart D, et al. Colorectal multidisciplinary meetings: how do they affect the timeliness of treatment?[J]. Anz J Surg, 2017, 87(10): E112-5. doi: 10.1111/ans.13144
计量
- 文章访问数: 3714
- HTML全文浏览量: 445
- PDF下载量: 691